Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bermaz Auto buys back MYR 181,000 of stock, retains as treasury shares

Bermaz Auto buys back MYR 181,000 of stock, retains as treasury shares

BitgetBitget2026/10/01 10:03
  • Bermaz Auto bought back 200,000 ordinary shares on Oct. 1, 2026 at MYR 0.905 each.
  • Total consideration was MYR 181,000; the shares were retained as treasury stock.
  • Cumulative treasury shares rose to 44,855,300, equal to 3.83% of issued shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bermaz Auto Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3711318) on October 01, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

智通财经•2026/11/16 23:03
The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion

Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.

智通财经•2026/11/16 22:53